RNS Number : 7784K
Helios Underwriting Plc
02 September 2019



Helios Underwriting plc

("Helios" or the "Company")


Transaction in Own Shares


Total Voting Rights



Helios announces that on 30 August 2019 it purchased a total of 15,000 ordinary shares of 10 pence each in the Company ("ordinary shares") at an average price of 120 pence per ordinary share. The repurchased shares will be held in treasury.


This purchase forms part of the Company's share repurchase authority, granted at the shareholder meeting on 16 July 2019, with the objective of enhancing net asset value per share.


Following settlement of the above transaction, the Company's total number of ordinary shares in issue shall be 17,916,128 ordinary shares (excluding shares held in treasury), each carrying voting rights. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. The Company will also hold 372,778 ordinary shares in treasury, which do not carry voting rights.



For further information please contact:


Helios Underwriting plc

Nigel Hanbury - Chief Executive                                                  020 7863 6655 /

Arthur Manners - Chief Financial Officer                                   07754 965 917

Shore Capital

Robert Finlay/David Coaten                                                         020 7408 4090


About Helios

Helios provides a limited liability direct investment into the Lloyd's insurance market and is quoted on the London Stock Exchange's AIM market (ticker: HUW). Helios trades within the Lloyd's insurance market writing approximately £56m of capacity for the 2019 account. The portfolio provides a good spread of business being concentrated in property insurance and reinsurance. For further information please visit


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit